OMDA

AI Memo

Omada Health

As of 2026-07-08/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q1 beat and FY26 guidance raise need confirmation • 2026-10-06

Expected move: +1%

Biggest risk

The bear read is that much of the near-term narrative now depends on proving commercial conversion from PBM and Lilly relationships, and the negative immediate post-print share reaction reported by Investor's Business Daily suggests investors still want more evidence that partnerships and GLP-1 momentum will translate into durable growth and valuation upside.

Invalidation

Break below $16 or thesis failure.

What would change my mind?

The strongest bull read is that Q1 showed both demand and leverage: revenue grew 42% year over year, members reached 1.02 million, margins improved, and FY26 revenue and adjusted EBITDA guidance were raised, while the PBM and Lilly channel additions suggest Omada may be strengthening its position in GLP-1-enabled cardiometabolic care [#SEC-8K-2026-05-07].

Research note

Recommendation

—

Confidence

medium

As of

2026-07-08

Base target

$24

p=50%

Bull target

$30

p=25%

Bear target

$16

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q1 beat and FY26 guidance raise need confirmation
Operating leverage and liquidity reduce near-term financing pressure
GLP-1 channel expansion could extend member and revenue growth

BearKey bullets

Customer concentration language appears in the 10-Q metadata, which is a monitoring flag even though the packet does not provide a clean excerpt to size the exposure [#SEC-10Q-2026-05-08].
Execution risk on turning PBM and Lilly channel access into contracted employer revenue and sustained member growth.
GLP-1-related enthusiasm may be ahead of realized monetization, creating downside if uptake, retention, or economics disappoint.

WatchKey bullets

At $23.00 versus a stored median analyst target of about $23.33, the shares screen roughly fairly valued on current visible evidence; that keeps the setup in monitoring territory unless Omada delivers another guidance raise or clearer proof that its expanded channels are accelerating growth beyond what is already embedded.

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $24 (p=50%)

Bull/Bear spread: +27% / -32%

Vs latest close: Bull +27% · Base +1% · Bear -32%

Scenario probabilities

Bull Target: $30 (p=25%)Base Target: $24 (p=50%)Bear Target: $16 (p=25%)

Commentary

Primary-source evidence is strong for the Q1 operating update, but external reaction breadth is thin in the packet. The only recent stored news item framed the quarter as a sales beat plus Lilly tie-up but noted the shares fell after the print, which tempers the otherwise positive filing-based setup. With no social coverage packet, no analyst revision set, and a loose peer group, sentiment is best treated as cautious-to-neutral with low buzz rather than a high-conviction momentum signal.

As of 2026-07-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q1 beat and FY26 guidance raise need confirmation
Operating leverage and liquidity reduce near-term financing pressure
GLP-1 channel expansion could extend member and revenue growth

Scenarios

Bull Target (Scenario probability)

$30 / p=25% prob

Base Target (Scenario probability)

$24 / p=50% prob

Bear Target (Scenario probability)

$16 / p=25% prob

Price $24 as of 2026-07-17

Nearest Scenario: Base (∆ 1%)

Targets vs latest close: Bull +27% · Base +1% · Bear -32%

Sentiment & Exposure

News Sentiment (30d)

0.18

Social Sentiment (7d)

0.00

Short-term Catalysts

Next few weeks

Q1 beat and FY26 guidance raise need confirmation
2026-10-06
Omada reported Q1 revenue of $78 million, up 42% year over year, with gross margin up to 62%, adjusted EBITDA positive at $1 million, and FY26 revenue guidance raised to $322-$330 million from $312-$322 million; the next operating update is the key test of whether the post-IPO guide reset is durable rather than a one-quarter step-up [#SEC-8K-2026-05-07].
Prob 68% • Move 9% • Priced-in 55%

Long-term Catalysts

Months to a year

Operating leverage and liquidity reduce near-term financing pressure
2026-12-31
Q1 net loss narrowed to $3 million from $9 million, adjusted EBITDA turned positive, and cash and cash equivalents were $212 million, supporting a thesis that Omada can fund growth while improving profitability if utilization and gross margin remain stable [#SEC-8K-2026-05-07].
Prob 62% • Move 10% • Priced-in 50%
GLP-1 channel expansion could extend member and revenue growth
2027-07-08
Management said Omada now has relationships with all three leading PBMs and added Eli Lilly's Employer Connect as another employer channel for its GLP-1 Care Track and prescribing capabilities, which could expand employer adoption if conversion translates into sustained member adds and higher revenue per customer [#SEC-8K-2026-05-07].
Prob 60% • Move 14% • Priced-in 45%

Risks

Customer concentration language appears in the 10-Q metadata, which is a monitoring flag even though the packet does not provide a clean excerpt to size the exposure [#SEC-10Q-2026-05-08].
Execution risk on turning PBM and Lilly channel access into contracted employer revenue and sustained member growth.
GLP-1-related enthusiasm may be ahead of realized monetization, creating downside if uptake, retention, or economics disappoint.
Immediate post-earnings price action was negative despite a reported beat and partnership headlines, indicating skepticism around forward durability.
Peer set is loose and public-comp valuation support is weak, so multiple expansion may be limited without repeated beats.

Peers

Symbol	Summary
AHCO	AdaptHealth is a closer size match in healthcare services but is not a direct digital cardiometabolic peer; useful mainly as a small-cap healthcare-services sentiment and execution benchmark.
IART	Integra LifeSciences is also a loose comp by market cap and sector, but its device mix differs materially from Omada's virtual-care model, limiting valuation read-through.
ABT	Abbott is a broad healthcare benchmark rather than a direct peer; it is better used to frame quality expectations around scale, reimbursement relationships, and margin durability than to set OMDA multiples.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-07-08

AI Stock Memo: OMDA - Omada Health - RankAlpha